Your browser doesn't support javascript.
loading
Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine.
Bershteyn, Anna; Hanson, Melissa C; Crespo, Monica P; Moon, James J; Li, Adrienne V; Suh, Heikyung; Irvine, Darrell J.
Affiliation
  • Bershteyn A; Department of Materials Science and Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139-4307, USA.
J Control Release ; 157(3): 354-65, 2012 Feb 10.
Article in En | MEDLINE | ID: mdl-21820024
New subunit vaccine formulations with increased potency are of interest to improve immune responses against poorly immunogenic antigens, to avoid vaccine shortages in pandemic situations, and to promote dose-sparing of potent adjuvant molecules that can cause unacceptable side effects in prophylactic vaccination. Here we report strong class-switched, high avidity humoral immune responses elicited by a vaccine system based on poly(lactide-co-glycolide) micro- or nano-particles enveloped by PEGylated phospholipid bilayers, with protein antigens covalently anchored to the lipid surface and lipophilic adjuvants inserted in the bilayer coating. Strikingly, these particles elicited high endpoint antigen-specific IgG titers (>10(6)) sustained for over 100 days after two immunizations with as little as 2.5 ng of antigen. At such low doses, the conventional adjuvant alum or the molecular adjuvants monophosphoryl lipid A (MPLA) or α-galactosylceramide (αGC) failed to elicit responses. Co-delivery of antigen with MPLA or αGC incorporated into the particle bilayers in a pathogen-mimetic fashion further enhanced antibody titers by ~12-fold. MPLA provided the highest sustained IgG titers at these ultra-low antigen doses, while αGC promoted a rapid rise in serum IgG after one immunization, which may be valuable in emergencies such as disease pandemics. The dose of αGC required to boost the antibody response was also spared by particulate delivery. Lipid-enveloped biodegradable micro- and nano-particles thus provide a potent dose-sparing platform for vaccine delivery.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Immunoglobulin G / Ovalbumin / Vaccines, Subunit / Nanoparticles / Lipids / Antigens Limits: Animals Language: En Journal: J Control Release Journal subject: FARMACOLOGIA Year: 2012 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Immunoglobulin G / Ovalbumin / Vaccines, Subunit / Nanoparticles / Lipids / Antigens Limits: Animals Language: En Journal: J Control Release Journal subject: FARMACOLOGIA Year: 2012 Type: Article Affiliation country: United States